These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31656616)

  • 1. High-dose oral methylprednisolone for the treatment of multiple sclerosis relapses: cost-minimisation analysis and patient's satisfaction.
    Horta-Hernández AM; Esaclera-Izquierdo B; Yusta-Izquierdo A; Martín-Alcalde E; Blanco-Crespo M; Álvarez-Nonay A; Torralba M
    Eur J Hosp Pharm; 2019 Sep; 26(5):280-284. PubMed ID: 31656616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
    Burton JM; O'Connor PW; Hohol M; Beyene J
    Cochrane Database Syst Rev; 2012 Dec; 12():CD006921. PubMed ID: 23235634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
    Le Page E; Veillard D; Laplaud DA; Hamonic S; Wardi R; Lebrun C; Zagnoli F; Wiertlewski S; Deburghgraeve V; Coustans M; Edan G; ;
    Lancet; 2015 Sep; 386(9997):974-81. PubMed ID: 26135706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral administration of methylprednisolone powder for intravenous injection dissolved in water to treat MS and NMOSD relapses during COVID-19 pandemic in a real-world setting.
    Luetic GG; Menichini ML; Fernández Ó
    Mult Scler Relat Disord; 2021 Sep; 54():103148. PubMed ID: 34280680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Home administration of intravenous methylprednisolone for multiple sclerosis relapses: the experience of French multiple sclerosis networks.
    Créange A; Debouverie M; Jaillon-Rivière V; Taithe F; Liban D; Moutereau A; Clavelou P; Defer G
    Mult Scler; 2009 Sep; 15(9):1085-91. PubMed ID: 19556312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.
    Barnes D; Hughes RA; Morris RW; Wade-Jones O; Brown P; Britton T; Francis DA; Perkin GD; Rudge P; Swash M; Katifi H; Farmer S; Frankel J
    Lancet; 1997 Mar; 349(9056):902-6. PubMed ID: 9093250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis.
    Sharrack B; Hughes RA; Morris RW; Soudain S; Wade-Jones O; Barnes D; Brown P; Britton T; Francis DA; Perkin GD; Rudge P; Swash M; Katifi HA; Farmer S; Frankel JP
    J Neurol Sci; 2000 Feb; 173(1):73-7. PubMed ID: 10675582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
    Burton JM; O'Connor PW; Hohol M; Beyene J
    Cochrane Database Syst Rev; 2009 Jul; (3):CD006921. PubMed ID: 19588409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double-blind, non-inferiority trial.
    Hervás-García JV; Ramió-Torrentà L; Brieva-Ruiz L; Batllé-Nadal J; Moral E; Blanco Y; Cano-Orgaz A; Presas-Rodríguez S; Torres F; Capellades J; Ramo-Tello C
    Eur J Neurol; 2019 Mar; 26(3):525-532. PubMed ID: 30351511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility of oral methylprednisolone in the treatment of multiple sclerosis relapses: Results from the COPOUSEP trial.
    Michel M; Le Page E; Laplaud DA; Wardi R; Lebrun C; Zagnoli F; Wiertlewski S; Coustans M; Edan G; Chevreul K; Veillard D; ;
    Rev Neurol (Paris); 2022 Mar; 178(3):241-248. PubMed ID: 34598781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials.
    Liu S; Liu X; Chen S; Xiao Y; Zhuang W
    PLoS One; 2017; 12(11):e0188644. PubMed ID: 29176905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses.
    Ramo-Tello C; Tintoré M; Rovira A; Ramió-Torrenta L; Brieva L; Saiz A; Cano A; Carmona O; Hervás JV; Grau-López L
    Mult Scler; 2016 Jan; 22(1):117-21. PubMed ID: 26540732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Would it be recommended treating multiple sclerosis relapses with high dose oral instead intravenous steroids during the COVID-19 pandemic? Yes.
    Segamarchi C; Silva B; Saidon P; Garcea O; Alonso R
    Mult Scler Relat Disord; 2020 Nov; 46():102449. PubMed ID: 32853893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.
    Ramo-Tello C; Grau-López L; Tintoré M; Rovira A; Ramió i Torrenta L; Brieva L; Cano A; Carmona O; Saiz A; Torres F; Giner P; Nos C; Massuet A; Montalbán X; Martínez-Cáceres E; Costa J
    Mult Scler; 2014 May; 20(6):717-25. PubMed ID: 24144876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of response of multiple sclerosis (MS) relapse to oral high-dose methylprednisolone: usefulness of MS functional composite and Expanded Disability Status Scale.
    Pascual AM; Boscá I; Coret F; Escutia M; Bernat A; Casanova B
    Eur J Neurol; 2008 Mar; 15(3):284-8. PubMed ID: 18290849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prospective assessment of the treatment of multiple sclerosis relapses with oral high-dose methylprednisolone: response and tolerability data].
    Pascual AM; Boscá I; Escutia M; Bernat A; Coret F; Casanova B
    Neurologia; 2008 Mar; 23(2):73-7. PubMed ID: 17641984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
    Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
    Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial.
    Ozakbas S; Cinar BP; Kosehasanoğullari G; Kahraman T; Oz D; Kursun BB
    Clin Neurol Neurosurg; 2017 Sep; 160():69-72. PubMed ID: 28689102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.